Selectivity in the impact of P-glycoprotein upon pulmonary absorption of airway-dosed substrates: A study in ex vivo lung models using chemical inhibition and genetic knockout

Journal of Pharmaceutical Sciences

Volumn 102, Issue 9, 2013, Pages 3382-3394

  Al Jayyoussi, Ghaith ^a   Price, Daniel F ^a   Francombe, Danielle ^a   Taylor, Glyn ^a   Smith, Mathew W ^a   Morris, Chris ^a,c   Edwards, Chris D ^b   Eddershaw, Peter ^b   Gumbleton, Mark ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

^c UNIVERSITY OF EAST ANGLIA   (United Kingdom)

Author keywords

Active transport; Efflux pumps; Isolated perfused mouse lung (IPML); Isolated perfused rat lung (IPRL); Passive transport; Permeability; Pulmonary delivery; Transporters

Indexed keywords

DIGOXIN; LOPERAMIDE; MULTIDRUG RESISTANCE PROTEIN; RHODAMINE 123; SAQUINAVIR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; DRUG ABSORPTION; DRUG DISPOSITION; DRUG PENETRATION; DRUG TRANSPORT; EX VIVO STUDY; GENE INACTIVATION; GENOTYPING TECHNIQUE; IN VITRO STUDY; ISOTOPE LABELING; LIQUID SCINTILLATION COUNTING; LUNG MODEL; LUNG PERFUSION; MALE; MOUSE; NONHUMAN; RAT;

ACTIVE TRANSPORT; EFFLUX PUMPS; ISOLATED PERFUSED MOUSE LUNG (IPML); ISOLATED PERFUSED RAT LUNG (IPRL); PASSIVE TRANSPORT; PERMEABILITY; PULMONARY DELIVERY.; TRANSPORTERS;

ANIMALS; ANTI-ARRHYTHMIA AGENTS; ANTIDIARRHEALS; BIOLOGICAL TRANSPORT; DIGOXIN; DOGS; GENE KNOCKOUT TECHNIQUES; HIV PROTEASE INHIBITORS; HUMANS; LOPERAMIDE; LUNG; MADIN DARBY CANINE KIDNEY CELLS; MALE; MICE; MICE, KNOCKOUT; P-GLYCOPROTEIN; P-GLYCOPROTEINS; PERMEABILITY; RATS; RATS, SPRAGUE-DAWLEY; RHODAMINE 123; SAQUINAVIR;

EID: 84881609385     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23587     Document Type: Article

References (40)

1. Gumbleton M, Al-Jayyoussi G, Crandon-Lewis A, Francombe D, Kreitmeyr K, Morris CJ, Smith MW. 2011. Spatial expression and functionality of drug transporters in the intact lung: Objectives for further research. Adv Drug Deliv Rev 63:110-118.
2. Bosquillon C. 2010. Drug transporters in the lung-Do they play a role in the biopharmaceutics of inhaled drugs? J Pharm Sci 99(5):2240-2255.
3. Salomon JJ, Ehrhardt C. 2012. Organic cation transporters in the blood-air barrier: Expression and implications for pulmonary drug delivery. Ther Deliv 3(6):735-747.
4. Campbell L, Abulrob AN, Kandalaft LE, Plummer S, Hollins AJ, Gibbs A, Gumbleton M. 2003. Constitutive expression of P-glycoprotein in normal lung alveolar epithelium and functionality in primary alveolar epithelial cultures. J Pharmacol Exp Ther 304:441-452.
5. Brady JM, Cherrington NJ, Hartley DP, Buist SC, Li N, Klaassen CD. 2002. Tissue distribution and chemical induction of multiple drug resistance genes in rats. Drug Metab Dispos 30:838-844.
6. Bleasby K, Castle JC, Roberts CJ, Cheng C, Bailey WJ, Sina JF, Kulkarni AV, Hafey MJ, Evers R, Johnson JM, Ulrich RG, Slatter JG. 2006. Expression profiles of 50 xenobiotic transporter genes in humans and pre-clinical species: A resource for investigations into drug disposition. Xenobiotica 36:963-988.
7. Stone KC, Mercer RR, Freeman BA, Chang LY, Crapo JD. 1992. Distribution of lung cell numbers and volumes between alveolar and nonalveolar tissue. Am Rev Respir Dis 146(2):454-456.
8. Haies DM, Gil J, Weibel ER. 1981. Morphometric study of rat lung cells. I. Numerical and dimensional characteristics of parenchymal cell population. Am Rev Respir Dis 123:533-541.
9. Crapo JD, Barry BE, Gehr P, Bachofen M, Weibel ER. 1982. Cell number and cell characteristics of the normal human lung. Am Rev Respir Dis 126:332-337.
10. Cordon-Cardo C, O'Brien JP, Boccia J, Casals D, Bertino JR, Melamed MR. 1990. Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem 38:1277-1287.
11. Valk PVD, Kalken CKV, Ketelaars H, Broxterman HJ, Scheffer G, Kuiper CM, Tsuruo T, Lankelma J, Meijer CJLM, Pinedo HM, Scheper RJ. 1990. Distribution of multi-drug resistance-associated P-glycoprotein in normal and neoplastic human tissues analysis with 3 monoclonal antibodies recognizing different epitopes of the P-glycoprotein molecule. Ann Oncol 1(1):56-64.
12. Lechapt-Zalcman E, Hurbain I, Lacave R, Commo F, Urban T, Antoine M, Milleron B, Bernaudin JF. 1997. MDR1-Pgp 170 expression in human bronchus. Eur Respir J 10:1837-1843.
13. Scheffer GL, Pijnenborg AC, Smit EF, Muller M, Postma DS, Timens W, van der Valk P, de Vries EG, Scheper RJ. 2002. Multidrug resistance related molecules in human and murine lung. J Clin Pathol 55:332-339.
14. Endter S, Becker U, Daum N, Huwer H, Lehr CM, Gumbleton M, Ehrhardt C. 2007. P-glycoprotein (MDR1) functional activity in human alveolar epithelial cell monolayers. Cell Tissue Res 328:77-84.
15. Bosquillon C. 2010. Drug transporters in the lung-Do they play a role in the biopharmaceutics of inhaled drugs? J Pharm Sci 99:2240-2255.
16. Madlova M, Bosquillon C, Asker D, Dolezal P, Forbes B. 2009. In-vitro respiratory drug absorption models possess nominal functional P-glycoprotein activity. J Pharm Pharmacol 61:293-301.
17. Ehrhardt C, Kneuer C, Laue M, Schaefer UF, Kim KJ, Lehr CM. 2003. 16HBE14o- human bronchial epithelial cell layers express P-glycoprotein, lung resistance-related protein, and caveolin-1. Pharm Res 20:545-551.
18. Tronde A, Norden B, Jeppsson AB, Brunmark P, Nilsson E, Lennernas H, Bengtsson UH. 2003. Drug absorption from the isolated perfused rat lung-Correlations with drug physicochemical properties and epithelial permeability. J Drug Target 11:61-74.
19. Tronde A, Norden B, Marchner H, Wendel AK, Lennernas H, Bengtsson UH. 2003. Pulmonary absorption rate and bioavailability of drugs in vivo in rats: Structure-absorption relationships and physicochemical profiling of inhaled drugs. J Pharm Sci 92:1216-1233.
20. Manford F, Riffo-Vasquez Y, Spina D, Page CP, Hutt AJ, Moore V, Johansson F, Forbes B. 2008. Lack of difference in pulmonary absorption of digoxin, a P-glycoprotein substrate, in mdr1a-deficient and mdr1a-competent mice. J Pharm Pharmacol 60:1305-1310.
21. Morris CJ, Smith MW, Griffiths PC, McKeown NB, Gumbleton M. 2011. Enhanced pulmonary absorption of a macromolecule through coupling to a sequence-specific phage display-derived peptide. J Control Release 151:83-94.
22. Sakagami M, Omidi Y, Campbell L, Kandalaft LE, Morris CJ, Barar J, Gumbleton M. 2006. Expression and transport functionality of FcRn within rat alveolar epithelium: A study in primary cell culture and in the isolated perfused lung. Pharm Res 23(2):270-279.
23. Sakagami M. 2006. In vivo, in vitro and ex vivo models to assess pulmonary absorption and disposition of inhaled therapeutics for systemic delivery. Adv Drug Deliv Rev 58(9-10):1030-1060.
24. Francombe DT, Taylor G, Somers G, Edwards CD, Gumbleton M. 2008. Functional role of P-gp efflux in limiting pulmonary drug absorption within an intact lung: application of an isolated perfused rat lung model. Respiratory drug delivery. Scottsdale, Arizona; May 11-15, 2008; pp 461-464.
25. Lanman RC, Gillilan RM, Schanker LS. 1973. Absorption of cardiac glycosides from the rat respiratory tract. J Pharmacol Exp Ther 187:105-111.
26. Matsson P, Pedersen JM, Norinder U, Bergstrom CA, Artursson P. 2009. Identification of novel specific and general inhibitors of the three major human ATP-binding cassette transporters P-gp, BCRP and MRP2 among registered drugs. Pharm Res 26(8):1816-1831.
27. Vethanayagam RR, Wang H, Gupta A, Zhang Y, Lewis F, Unadkat JD, Mao Q. 2005. Functional analysis of the human variants of breast cancer resistance protein: I206L, N590Y, and D620N. Drug Metab Dispos 33(6):697-705.
28. Zamek-Gliszczynski MJ, Bedwell DW, Bao JQ, Higgins JW. 2012. Characterization of SAGE Mdr1a (P-gp), Bcrp, and Mrp2 knockout rats using loperamide, paclitaxel, sulfasalazine, and carboxydichlorofluorescein pharmacokinetics. Drug Metab Dispos 40(9):1825-1833.
29. Nare B, Prichard RK, Georges E. 1994. Characterization of rhodamine 123 binding to P-glycoprotein in human multidrug-resistant cells. Mol Pharmacol 45(6):1145-1152.
30. Doppenschmitt S, Spahn-Langguth H, Regardh CG, Langguth P. 1999. Role of P-glycoprotein-mediated secretion in absorptive drug permeability: An approach using passive membrane permeability and affinity to P-glycoprotein. J Pharm Sci 88(10):1067-1072.
31. Melchior DL, Sharom FJ, Evers R, Wright GE, Chu JWK, Wright SE, Chu X, Yabut J. 2012. Determining P-glycoprotein-drug interactions: Evaluation of reconstituted P-glycoprotein in a liposomal system and LLC-MDR1 polarized cell monolayers. J Pharmacol Toxicol Methods 65:64-74.
32. Bachmeier CJ, Spitzenberger TJ, Elmquist WF, Miller DW. 2005. Quantitative assessment of HIV-1 protease inhibitor interactions with drug efflux transporters in the blood-brain barrier. Pharm Res 22:1259-1268.
33. Varma MV, Panchagnula R. 2005. Enhanced oral paclitaxel absorption with vitamin E-TPGS: Effect on solubility and permeability in vitro, in situ and in vivo. Eur J Pharm Sci 25:445-453.
34. Patton JS, Brain JD, Davies LA, Fiegel J, Gumbleton M, Kim KJ, Sakagami M, Vanbever R, Ehrhardt C. 2010. The particle has landed-Characterizing the fate of inhaled pharmaceuticals. J Aerosol Med Pulm Drug Deliv 23(Suppl 2):S71-S87.
35. Mehta R, Kelleher D, Preece A, Hughes S, Crater G. 2013. Effect of verapamil on systemic exposure and safety of umeclidinium and vilanterol: A randomized and open-label study. Int J Chron Obstruct Pulmon Dis 8:159-167.
36. Valenzuela B, Nácher A, Casabó VG, Martín-Villodre A. 2001. The influence of active secretion processes on intestinal absorption of salbutamol in the rat. Eur J Pharm Biopharm eV 52:31-37.
37. Chang C, Bahadduri PM, Polli JE, Swaan PW, Ekins S. 2006. Rapid identification of P-glycoprotein substrates and inhibitors 34:1976-1984.
38. Crowe A, Tan AM. 2012. Oral and inhaled corticosteroids: Differences in P-glycoprotein (ABCB1) mediated efflux. Toxicol Appl Pharmacol 260:1-9.
39. Dilger K, Schwab M, Fromm MF. 2004. Identification of budesonide and prednisone as substrates of the intestinal drug efflux pump P-glycoprotein. Inflamm Bowel Dis 10:578-583.
40. Cooray HC, Shahi S, Cahn AP, van Veen HW, Hladky SB, Barrand Ma. 2006. Modulation of P-glycoprotein and breast cancer resistance protein by some prescribed corticosteroids. Eur J Pharmacol 531:25-33.